Semaglutide is the GLP-1 agonist that revolutionized weight loss treatment. Following FDA resolution of shortages in 2025 and subsequent compounding restrictions, research-grade semaglutide has seen significant demand increases.
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity for weight management.
Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
This peptide is FDA-approved and available by prescription. It can be obtained through traditional pharmacies with a valid prescription, and is also available through compounding pharmacies for customized formulations.
Fat metabolism support
Targeted fat reduction
Fat metabolism
Appetite regulation
Browse our verified directory of pharmacies, telehealth providers, and research vendors.
Browse ProvidersThe information provided about SEMAGLUTIDE is for educational and research purposes only. This content is not intended as medical advice, diagnosis, or treatment recommendation.SEMAGLUTIDE is a research compound and may not be approved for human use. Always consult with a qualified healthcare provider before considering any peptide therapy. The Peptide List does not sell peptides or provide medical services.
This website is for informational purposes only and does not constitute medical advice. Consult a licensed physician before using any peptides. Provider listings do not constitute endorsements. None of the statements on this site have been evaluated by the FDA.